News

Filter All 2025 2023 2022 2021 2020 2019 2018 2017
March 2025 OncoZenge AB enters exclusive agreement with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe January 2025 Steincares and Molteni Farmaceutici Expand Access to Pain Treatment in Latin America January 2025 OncoZenge AB has entered into a non-binding agreement with the intention to partner with Molteni Farmaceutici for commercialization of BupiZenge™ in Europe

Information on How to Report Adverse Drug Reactions

Reporting Adverse Events
To consult the adverse event reporting policy, click here.

Medical information

Molteni Farmaceutici provides updated scientific information about its products. For medical inquiries, please contact us via email. We do not offer individual consultations; for treatment, consult your physician.

medicalenquiries@moltenifarma.it

Join Our Team

Join us to grow and innovate together: we value the talent and entrepreneurial spirit of every individual.
Spontaneous Application
To consult the legal information on careers, click here.

Contact Molteni

For general inquiries about Molteni Farmaceutici, please write to the following email address. We will respond to all questions as soon as possible.
info@moltenifarma.it